Skip to content
lifestyle.eastmnweeklynews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immuneering Corporation
Immuneering Corporation Announces Grants of Inducement Awards
July 17, 2026
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
June 1, 2026
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026
←
Previous Page
1
2